Connect with us

Hi, what are you looking for?

Friday, Dec 3, 2021
Mugglehead Magazine
Cannabis & psychedelics industry news based in Vancouver, B.C.
  • Loading stock data...

Medical and Pharmaceutical

Cannabis-based medicine could be used to treat Tourette syndrome: study

While there’s only limited data on the effects of cannabis in minors, researchers suggest it as an alternative to surgery in severe cases

Cannabis-based medicine could be used to treat Tourette syndrome - study
Image via Deposit Photos

Cannabis-based medicines are effective in treating tics and other symptoms in people suffering from Tourette syndrome.

In a recent review published in the Polish Journal of Neurology and Neurosurgery, researchers gathered and analyzed studies on cannabis easing symptoms of the disease. They found that while there’s still more research to be done, cannabis-based treatments were considered safe and well-tolerated when sticking to the strategy of “start low, go slow.”

Gilles de la Tourette syndrome (GTS) is a neurological disorder, typically diagnosed during childhood, that causes tics or involuntary movements or speech. It’s normally accompanied by other psychiatric conditions like anxiety or depression.

So far, there is no known treatment for the condition.

People who suffer from it are given antipsychotics to ease tics, but such medication hasn’t shown to be fully effective and usually cause unwanted side effects, reads the study review authored by researchers at the University of Warsaw.

“Importantly, we present results regarding therapy of tics as well as psychiatric comorbidities and allude to studies examining the involvement of the endocannabinoid system (ECS) in the pathophysiology of GTS,” the authors explain.

Read more: Cannabis eases severe morning sickness: study

Read more: Nearly half of US breast cancer patients use cannabis medically, but don’t tell their doctor: study

For the study, researchers looked into 22 studies on Tourette syndrome and cannabis-based medicine. Then they organized the studies depending on design, such as systematic reviews of randomized controlled trials, case reports, case series and expert opinion reviews.

CB1 and CB2 receptors are central components of the endocannabinoid system, which is involved in the regulation of many bodily functions. Image via ‘Cannabis-based medicine in the treatment of patients with Gilles de la Tourette syndrome’

Cannabis-based medicines in the review included cannabis flower from the black market, THC oil, Lu AG64066, nabiximol spray and medical cannabis.

In one retrospective study with 98 patients diagnosed with Tourette syndrome that used cannabis-based medicine, it was found that 66 per cent preferred cannabis flower over other methods such as THC or nabiximol, since it was more effective and tolerated. High-THC strains were more effective.

Nabiximol is a spray with a half-and-half concentration of THC and CBD, and is licensed in most European countries for the treatment of impaired movement that can occur as the result of multiple sclerosis. In a study on the spray, researchers found a 22-per-cent reduction in tics, and patient quality of life improved by 70 per cent.

“Moreover, the results of randomized controlled trials are conflicting, as smaller studies with THC showed significant tic reduction, while another study using the endocannabinoid modulator Lu AG06466 failed to demonstrate efficacy in tic reduction,” reads the review.

The authors say that while there’s only limited data on how cannabis-based medicine could affect minors, children severely affected by the condition should consider trying it before accessing more drastic measures like surgical interventions.

Read more: Cannabis helps manage painful endometriosis symptoms: study

Read more: 80% of patients report reduced symptoms after using cannabis oil: Khiron study

The endocannabinoid system plays an integral role in regulating neurotransmitters, and influences the functioning of almost every other system in the body.

Previous neuroimaging studies have found evidence for the involvement of the endocannabinoid system in Tourette syndrome. In 1988, cannabis was reported to ease symptoms of the disease for the first time.

 

Follow Mugglehead on Twitter

Like Mugglehead on Facebook

Follow Natalia Buendia Calvillo on Twitter

natalia@mugglehead.com

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Health and Safety

Science doesn't know yet, but one psychedelic researcher is chasing clues to see if it can

Canada

As more medium-to-small producers came into play this year, great weed started hitting legal shelves at fairer prices

Culture

Punishments for possession include caning and the death penalty. Despite a global trend of reform, The Fine City remains staunch in its anti-drug stance

Analysis

While legal weed businesses decry enforcement of their accounts, the platform says it's keeping its all-ages community safe